The American scholar, William Arthur Ward, once wrote: “The pessimist complains about the wind; the optimist expects it to change; and the realist adjusts the sails.”In today’s market, the price of a stock is influenced by more than just conventional factors. We live in an evolving world experiencing swift and transformative change. For this reason, an investor needs a more comprehensive way to analyze investment opportunities.This is exactly why TipRanks created the Smart Score – an all-encompassing way to evaluate a stock. The Smart Score aggregates eight important factors, some of which are unfamiliar to the average investor, such as hedge fund and insider activity. Each stock is then ranked from 1 to 10, with 10 being the highest, so that an investor can keep up and make a more informed decision.With this in mind, Using TipRanks’ database, we identified three stocks that have earned the “Perfect 10” Smart Score. Not...
Karim Hijazi, Prevailion CEO, alongside Yahoo Finance's Dan Howley, join The First Trade with Alexis Christoforous and Brian Sozzi to discuss the possibility of Microsoft buying TikTok's operations in the United States. Both Hijazi and Howley also weigh in on what this means for the social media industry overall and potential buyers beyond Microsoft....
Evermore Global Advisors recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Evermore Global Value Fund posted a return of 10.35% for the quarter, underperforming its benchmarks, the MSCI All Country World Index ex USA (MSCI ACWI ex USA), the MSCI All Country World Index (MSCI ACWI), and […]...
Merck & Co., Inc's (NYSE: MRK) internal pipeline seems underappreciated by the market, and the loss of exclusivity of its cancer immunology drug Keytruda appears priced in, according to Goldman Sachs.The Merck Analyst: Terence Flynn upgraded Merck from Neutral to Buy and raised the price target from $91 to $105.The Merck Thesis: The market seems to be underappreciating a potential opportunity of between $13 billion and $18 billion in pipeline assets, Flynn said in the Monday upgrade note. (See his track record here.)Merck has developed several earlier stage cancer assets that can be used in combination with Keytruda or in patients who do not respond to Keytruda, the analyst said, adding that Phase I and II data may emerge at the ESMO conference in September and over the next year.Phase II and III trials are underway for Islatravir for both treatment and prevention of HIV. Phase II prevention data is expected...
